Trials / Completed
CompletedNCT00479778
Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
An Open Label, Randomized, Multicenter Study To Compare Bazedoxifene Steady-State Exposures Obtained With 2 Bazedoxifene Acetate/Conjugated Estrogen Formulations In Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens. It is an open label study with no placebo control or comparator drugs. Subjects will take one dose of the investigation formulation daily for 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bazedoxifene/conjugated estrogens |
Timeline
- Start date
- 2007-04-01
- Completion
- 2007-07-01
- First posted
- 2007-05-28
- Last updated
- 2007-12-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00479778. Inclusion in this directory is not an endorsement.